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Background: FDG-PET/CT is part of the standard diagnostic management of a patients with a large variety of
common and less common malignant tumors, based on the increased glucose metabolism within tumors.
Case presentation: A hybrid fluorodeoxyglucose positron emission tomography and computed tomography
(FDG-PET/CT) was performed in a neurofibromatosis patient to rule out relapse of malignant peripheral nerve sheet
tumor. The scan revealed non-malignant neurofibromas, a testis seminoma and hypermetabolic syphilitic granulomata.
Conclusion: This case stresses the need to rule out infectious diseases when atypical hypermetabolic lesions are present.
Keywords: Syphilis, PET, Fluorodeoyglucose, Neurofibromatosis, Testicular seminomaBackground
FDG-PET/CT is part of the standard diagnostic manage-
ment of a patients with a large variety of common and
less common malignant tumors, based on the increased
glucose metabolism within tumors. It is useful for de-
tecting malignant transformation of neurofibromas to
MPNST, as malignant MPNST is characterized by higher
FDG uptake. A cut-off maximum standardized uptake
value (SUVmax) of 3.5 discriminates neurofibroma from
MPNST (sensitivity: 89%; specificity 95%) [1]. High FDG
uptake can be seen in non-neoplastic tissues, for instance
in inflammatory or infectious lesions. Interpretation of
FDG-PET images should thus be done with full knowledge
of the case record of the patient.
Case presentation
A 32 year-old homosexual Caucasian male with neuro-
fibromatosis type I (NF1), café-au-lait patches and
known superficial and deep neurofibromas consulted us
for unexplained fatigue and weight loss. History and* Correspondence: patrick.schoffski@uzleuven.be
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unless otherwise stated.biochemistry were unremarkable. His clinical examin-
ation revealed known signs of NF1 and a nodular ap-
pearance of his right testicle.
FDG-PET/CT was performed to exclude the presence
of a NF1-related malignancy (e.g., malignant peripheral
nerve sheet tumor, MPNST). It revealed multiple hyper-
metabolic lesions in the following sites: right scrotum,
omentum, peritoneum, neuroforamen C5/C6, sternum,
ribs, both lungs and mediastinum (Figure 1). Based on
these findings testicular cancer with abdominal, pulmon-
ary and bone involvement had to be ruled out. Scrotal
ultrasound showed a multinodular mass in the right tes-
ticle and ipsilateral hypoechogenic inguinal nodules.
Serum tumor markers were normal.
The patient underwent a simultaneous orchiectomy
and diagnostic laparoscopic resection of inguinal and
omental lesions. Histology revealed a 2.6 cm testicular
seminoma with epididymal invasion. The surrounding
stroma, funiculus spermaticus and resected omental and
inguinal lesions showed a lymphocytic and granulomatous
infiltrate, which was initially interpreted as a sarcoid-like
reaction or sarcoidosis. There was no evidence for neuro-
fibroma or sarcoma in any of the tissue samples.
A broad laboratory investigation was performed to rule
out some common causes of granulomata. Serologies forLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Figure 1 FDG_PET/C T findings. (A) FDG-PET/CT performed at diagnosis (large arrow: hypermetabolic seminoma testis; arrowhead: low FDG-uptake
in neurofibroma; small arrow: syphilitic granulomatous lesions); (B) FDG-PET/CT after orchidectomy, diagnostic laparoscopy and two week treatment
with doxocycline, showing persistant uptake only in neurofibromas (arrowheads); (C) PET/CT fusion of primary seminoma; (D) hematoxylin/eosin stain
of seminoma; and (E) inguinal granuloma.
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hepatitis B/C, HIV and HTLV-1 were normal. Tuberculosis
was ruled out by specific staining. Serology for Treponema
pallidum was positive (Treponema pallidum specific anti-
body test+, rapid plasma reagin test+, titer 1/16). In retro-
spect, the patient had no history of urogenital complaints
or ulcus durum, rash or arthralgia.
We thus interpreted the hypermetabolic granulomatous
lesions as active syphilis (primo-infection), for which
antibiotic treatment of both the patient (doxycycline
200 mg/day p.o. for 2 weeks because of an IgE-mediated al-
lergy to penicillin) and his serologically-negative partner
was initiated. To confirm the working hypothesis of meta-
bolically active syphilis and to rule out distant spread of
seminoma, FDG-PET/CT was repeated 21 days after end of
therapy, showing complete regression of all hypermetabolic
foci, except for known sites of neurofibroma.. We proposed
watchful waiting, adjuvant radiotherapy or systemic chemo-
therapy as options for stage I seminoma, and the patient
opted for adjuvant carboplatin AUC 7. He is currently in
three-monthly follow-up without clinical, serological or
radiological signs of relapse of testicular cancer progression
of NF1-related conditions or active syphilis.
FDG-PET/CT is increasingly used as whole body im-
aging modality in oncology, with high sensitivity and
specificity for a number of malignancies. It is useful for
detecting malignant transformation of neurofibromas toMPNST, as malignant MPNST is characterized by higher
FDG uptake. A cut-off maximum standardized uptake
value (SUVmax) of 3.5 discriminates neurofibroma from
MPNST (sensitivity: 89%; specificity 95%)1. Seminoma
testis is highly FDG-avid (average SUVmean 9.2) [2]. FDG-
PET/CT is able to detect seminomatous lesions, is gener-
ally not recommended for seminoma staging [3] but is
useful for characterization of residual masses after chemo-
therapy (sensitivity: 80%; specificity 100%) [4].
The experience with FDG-PET/CT in syphilis is very
limited but hypermetabolic syphilitic lesions in bone,
lymph nodes, lung, aorta [5], rectum and brain have
been reported only in individual patients. In patients
presenting with multiple pathologies quantitative evalu-
ation of the FDG PET images might be of use to ascer-
tain the presence of multiple synchronous diseases. One
interesting study [6] proposed a cut off value of 40% for
the difference between two lesions to discriminate me-
tastases from a synchronous secondary primary tumor.
When applying this treshold to this patient this suggests
that the neurofibromas are not related to the other foci
but it does not suggest that the granulomatous lesions
are not related to the testis tumor, which is similar to
the visual interpretation of the data. Only 3 cases have
been described in the literature with a testicular tumor
in a NF-1 patient, so occurrence of seminoma in NF1
patients has to be regarded as fortuitous [7-9].
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FDG-PET/CT detected an incidental seminoma testis in
a NF1-patient with simultaneous hypermetabolic thoraco-
abdomino-pelvic lesions, which were first attributed to the
seminoma, then considered to be sarcoid-like lesions ac-
cording to histology, and were ultimately diagnosed as
syphilitic granulomas based on serology and functional
imaging before and after antibiotic treatment. FDG-PET/
CT cannot differentiate between active inflammation
(infectious or not) and malignancy, so metabolic findings
always have to be interpreted with caution and in the con-
text of additional clinical information, as shown in our
complex case. Infectious diseases should be ruled out in
cases with aspecific pathological findings.
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